Single Cell-Derived Prostate Organoids for Disease Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer models, particularly for prostate cancer, fail to adequately represent the molecular and cellular diversity of human cancers, making it difficult to understand disease progression and develop effective therapies due to the inability to propagate primary tissues in vitro and the lack of complexity in existing models.
Innovation Solution
The method involves creating in vitro prostate organoids from primary prostate cancer tissue using a differentiation medium and an organoid medium supplemented with growth factors like BPE, epinephrine, bFGF, and EGF, which are cultured in a 3D extracellular matrix to produce organoids that mimic the prostate microenvironment, allowing for the identification of anticancer agents and personalized therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If primary tissues are used for cancer studies, then molecular and cellular diversity is preserved, but the ability to propagate tissues in vitro is lost
Solution Approach 1:
The patent creates organoid copies that replicate the molecular and cellular diversity of primary prostate cancer tissues. These organoids are generated by culturing dissociated cancer cells in 3D extracellular matrix under specific conditions that induce self-organization into tissue-like structures, providing propagatable models that maintain the genetic and phenotypic characteristics of the original primary tumors
Solution Approach 2:
The patent employs parameter changes in culture conditions to enable tissue propagation. By optimizing parameters such as extracellular matrix composition, growth factors (bFGF, EGF, insulin, hydrocortisone), and culture architecture (3D vs monolayer), the method transforms dissociated cancer cells into propagatable organoids that maintain tissue diversity while enabling in vitro expansion
2Ease of operation
If cell lines grown in monolayers are used, then ease of culture is improved, but the complexity of the cancer microenvironment is lost
Solution Approach 1:
The patent transitions from 2D monolayer culture to 3D organoid culture by embedding dissociated cancer cells in extracellular matrix. This dimensional change enables the formation of complex microenvironments with multiple cell types and spatial organization while maintaining ease of culture through standardized protocols
Solution Approach 2:
The patent uses composite culture systems combining extracellular matrix with multiple growth factors (bFGF, EGF, insulin, hydrocortisone) to recreate the complexity of the cancer microenvironment. This composite approach maintains ease of operation through defined composition while capturing the biological complexity of primary tumors
3Reliability
If genetically engineered mouse models are used, then disease progression can be studied, but the diversity of human cancer mechanisms is not represented
Solution Approach 1:
The patent creates human cancer organoid copies that directly replicate human tumor genetics and mechanisms rather than using mouse models. These organoids maintain the original human cancer's molecular diversity and can be used to study disease progression while preserving human-specific biological mechanisms
Data Source
AI summary
The present invention relates to organoids derived from a single cell, such as a prostate cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and methods of personalized treatment for prostate cancer. The invention further provides a humanized mouse comprising a prostate organoid derived from a patient's prostate cell.